Heartflow, Inc. (NASDAQ:HTFL) Receives $38.60 Consensus Price Target from Brokerages

Heartflow, Inc. (NASDAQ:HTFL) has earned a consensus recommendation of “Hold” from the seven brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $38.60.

HTFL has been the topic of several recent research reports. Zacks Research raised Heartflow to a “hold” rating in a research report on Wednesday, September 3rd. Stifel Nicolaus upped their price objective on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Piper Sandler initiated coverage on Heartflow in a research report on Tuesday, September 2nd. They set an “overweight” rating and a $38.00 price objective on the stock. Weiss Ratings started coverage on shares of Heartflow in a report on Saturday, November 1st. They issued a “sell (d+)” rating for the company. Finally, JPMorgan Chase & Co. increased their price target on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th.

Heartflow Trading Up 3.4%

NASDAQ HTFL opened at $27.31 on Friday. Heartflow has a one year low of $25.75 and a one year high of $41.22. The firm’s 50-day simple moving average is $34.29.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Friday, September 19th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The firm had revenue of $43.42 million for the quarter, compared to analysts’ expectations of $43.20 million.

Hedge Funds Weigh In On Heartflow

Several institutional investors and hedge funds have recently bought and sold shares of the company. Zimmer Partners LP acquired a new position in shares of Heartflow during the third quarter worth $673,000. Alyeska Investment Group L.P. purchased a new position in Heartflow during the 3rd quarter worth $2,861,000. Summit Partners Public Asset Management LLC acquired a new position in Heartflow during the 3rd quarter valued at about $28,559,000. Millennium Management LLC purchased a new stake in Heartflow in the third quarter valued at about $3,904,000. Finally, Jain Global LLC purchased a new stake in Heartflow in the third quarter valued at about $1,050,000.

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.